<DOC>
	<DOC>NCT01329380</DOC>
	<brief_summary>This study of Humira will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug: - Unknown adverse drug reactions (especially important adverse drug reactions) - Incidence and conditions of occurrence of adverse reactions in the clinical setting - Factors that may affect the safety and effectiveness of Humira</brief_summary>
	<brief_title>Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<criteria>All patients with Ankylosing Spondylitis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey Contraindications according to the Package Insert Patients who have serious infections Patients who have tuberculosis Patients with a history of hypersensitivity to any ingredient of Humira Patients who have demyelinating disease or with a history of demyelinating disease Patients who have congestive cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>